CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to BioTime, Inc.	$ (36,411,660)	$ (43,882,835)	$ (21,425,703)
Net loss allocable to non-controlling interest	(7,367,440)	(9,026,291)	(3,880,157)
Adjustments to reconcile net loss attributable to BioTime, Inc. to net cash used in operating activities:
Acquired in-process research and development	0	17,458,766	0
Depreciation expense	1,050,651	656,759	386,457
Amortization of intangible assets	7,359,690	3,295,716	2,446,975
Amortization of deferred consulting fees	18,993	65,118	598,465
Amortization of deferred license fees	109,500	109,500	109,500
Amortization of deferred license, royalty and subscription revenues	(579)	(915,028)	(211,065)
Amortization of deferred grant revenues	0	0	(261,777)
Amortization of prepaid rent in common stock	84,586	84,586	0
Stock-based compensation	4,455,420	3,217,875	1,843,962
Reduction in receivables from the reversal of revenues	0	0	207,425
Amortization of discount on related party convertible debt	56,320	0	0
Amortization of deferred royalty fees (expense)	15	0	0
Loss/(gain) on sale or write-off of equipment	9,321	(5,120)	19,681
Bad debt expense	0	0	16,816
Deferred income tax benefit	(7,375,611)	(3,280,695)	0
Write-off for uncollectible receivables	(16,356)	0	0
Changes in operating assets and liabilities:
Accounts receivable, net	(73,784)	(180,933)	36,322
Grant receivable	11,325	560,286	(416,787)
Inventory	(87,328)	(123,378)	(4,141)
Prepaid expenses and other current assets	(86,427)	428,453	(228,370)
Other long term assets	0	(15,000)	0
Accounts payable and accrued liabilities	(469,755)	2,141,893	906,339
Accrued interest on convertible debt	4,226	0	0
Other long term liabilities	(160,250)	(57,824)	(26,088)
Deferred rent liabilities	61,283	(21,217)	(9,474)
Deferred revenues	(26,340)	(19,244)	212,102
Net cash used in operating activities	(38,854,200)	(29,508,613)	(19,679,518)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment	(483,097)	(2,277,168)	(400,810)
Cash acquired in connection with merger with XenneX	0	0	292,387
Construction in progress	(219,443)	0	0
Payment of transaction fees to Geron	0	(978,104)	0
Payment of syndication fees incurred	0	(376,250)	0
Cash proceeds from sale of equipment	9,242	30,900	4,500
Security deposit paid, net	(314,506)	(64,965)	(764)
Net cash used in investing activities	(1,007,804)	(3,665,587)	(104,687)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercises of stock options	219,500	46,000	286,552
Proceeds from exercises of warrants	50	0	0
Proceeds from sale of preferred shares	3,500,000	0	0
Proceeds from issuance of common shares	44,150,069	25,938,558	1,131,279
Fees paid on sale of common shares	(323,382)	(818,201)	(37,279)
Proceeds from sale of treasury stock and subsidiary warrants	15,156,561	3,841,749	282,826
Proceeds from issuance of related party convertible debt	470,856	0	0
Repayment of capital lease obligation	(26,210)	0	0
Proceeds from exercise of subsidiary stock options	7,799	0	0
Proceeds from sale of common shares of subsidiary	468,000	5,255,502	250,000
Net cash provided by financing activities	63,623,243	34,263,608	1,913,378
Effect of exchange rate changes on cash and cash equivalents	230,192	56,103	8,897
NET CHANGE IN CASH AND CASH EQUIVALENTS	23,991,431	1,145,511	(17,861,930)
CASH AND CASH EQUIVALENTS:
At beginning of year	5,495,478	4,349,967	22,211,897
At end of year	29,486,909	5,495,478	4,349,967
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during year for interest	91,047	3,090	315
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES :
Common shares issued to Cell Cure in exchange for Cell Cure shares	0	3,499,999	0
Common shares issued for consulting services	0	173,100	0
Common shares issued for rent	0	253,758	0
Intangible assets acquired from Geron	0	29,017,009	0
Common shares issued to Asterias upon consummation of asset contribution (Treasury shares)	0	34,985,163	0
Common shares acquired in connection with investment in LifeMap as part of Share Exchange and Contribution Agreement	0	0	2,750,003
Common shares issued as part of merger with XenneX	0	0	1,802,684
Employee options exercised with common stock	972,700	0	0
Capital expenditure funded by capital lease borrowing	115,000	0	0
Construction in progress in accounts payable and accrued expenses	186,727	0	0
Land lord receivable	(377,981)	0	0
Lease liability	377,981	0	0
Warrants issued to Asterias upon consummation of asset contribution	$ 0	$ 18,276,406	$ 0